G1 Therapeutics Announces Pricing of Offering of Common Stock

Genetics Investing

G1 Therapeutics (Nasdaq:GTHX), a clinical-stage oncology company, today announced the pricing of an underwritten public offering of 3,400,000 shares of its common stock at a public offering price of $29.50, for total gross proceeds of $100.3 million. All of the shares in the offering will be sold by G1 Therapeutics. As quoted in the press …

As quoted in the press release:

J.P. Morgan Securities LLC and Cowen and Company, LLC are serving as joint book-running managers for the offering. Needham & Company, LLC and Wedbush Securities Inc. are acting as lead managers for the offering. BTIG, LLC is acting as co-manager for the offering.

Click here to read the full press release.

g1 therapeutics j.p. morgan oncology public offering therapeutics underwritten public offering Genetics Investing